Literature DB >> 911030

Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck.

J Y Suen, S P Richman, R B Livingston, E M Hersh, R Craig, K Tonymon.   

Abstract

One hundred patients with advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck were treated with chemotherapy and BCG as adjuvant immunotherapy. The overall response rate was 35 per cent, and the median duration of response was seventeen weeks. BCG does not prolong duration of remission or survival time.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 911030     DOI： 10.1016/0002-9610(77)90381-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN： 0002-9610            Impact factor:   2.565


  1 in total

Review 1.  Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.

Authors:  Kelvin K W Chan; Anne-Marie Glenny; Jo C Weldon; Susan Furness; Helen V Worthington; Helen Wakeford
Journal:  Cochrane Database Syst Rev       Date:  2015-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.